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االستعمال االنتقائي للتصوير املقطعي ذو االنبعاث البيزوتروين املستخدم ملادة 
فلورو ديوكسي جلكوز والتصوير املقطعي يف معاجلة املرض املنتشر من سرطان 
القولون واملستقيم
نتائج مركز إقليمي
�ضدف جعفربهوئي، اآدم �ضامبريز، جيم�س ماندر، هيو باتري�ضون
abstract: Objectives: Computed tomography (CT) scans are routinely used for primary staging and disease 
surveillance in patients with colorectal cancer. However, these scans have limited sensitivity in some organs and can 
only detect lesions with morphological changes, whereas 18F-fluorodeoxyglucose-positron emission tomography 
(18F-FDG-PET) scans are able to detect areas of metabolic change before morphological changes appear. 
The aim of this study was to evaluate the impact of 18F-FDG-PET/CT scans over conventional imaging during 
preoperative work-ups or follow-ups in a selected group of patients. Methods: This retrospective cohort study, 
which took place between July 2009 and May 2011, assessed 1,043 patient records from the South East Scotland 
Cancer Network colorectal cancer database. A total of 102 patients who underwent 18F-FDG-PET/CT scans in 
addition to conventional imaging were included in the study. These patients had potentially resectable metastases, 
equivocal findings on CT scans and elevated carcinoembryonic antigen levels with negative conventional imaging. 
Results: Of the 102 patients included in the study, 22 underwent a preoperative 18F-FDG-PET/CT scan and 80 
underwent a follow-up 18F-FDG-PET/CT scan. In the preoperative scan group, the 18F-FDG-PET/CT scan had 
a major impact on 16 patients (72.75%) and no impact on six patients (27.25%). In the follow-up scan group, the 
18F-FDG-PET/CT scan had a major impact on 51 (63.75%), a minor impact on four (5%), no impact on 22 (27.5%) 
and a negative impact on three (3.75%) patients. Conclusion: The results of this study demonstrated that 18F-FDG-
PET/CT scans have a considerable effect on disease management when undertaken among indicated colorectal 
cancer patients. 
Keywords: 18F Fluorodeoxyglucose; Positron Emission Tomography; Colorectal Cancer; Metastases; Cancer 
Staging; Recurrence; Carcinoembryonic Antigen; United Kingdom.
امللخ�ص: الهدف: ت�ضتخدم فحو�ضات الت�ضوير املقطعي )CT( روتينيا يف التحديد االأويل ملر�س �رضطان القولون وامل�ضتقيم، ويف مراقبة 
يف  اإال  واالأذى  االإ�ضابات  عن  الك�ضف  ميكنها  وال  االأع�ضاء،  بع�س  يف  احل�ضا�ضية  حمدودة  الفحو�ضات  هذه  اأن  غري  ومتابعتهم  املر�ضى 
االأع�ضاء التي حدثت فيها بالفعل تغريات مورفولوجية. وعلى العك�س من ذلك، فاإن فحو�ضات الت�ضوير املقطعي ذو االنبعاث البيزوتروين 
اأي�ضية قبل  )18F-FDG-PET/CT( ميكنها الك�ضف عن مناطق اجل�ضم التي حدثت فيها تغريات  امل�ضتخدم ملادة فلورو ديوك�ضي جلكوز 
ظهور تغريات مورفولوجية فيها. وغر�س هذه الدرا�ضة هو تقييم تاأثري ومزايا فحو�ضات 18F-FDG-PET/CT على الفحو�ضات التقليدية 
يف مرحلة الت�ضخي�س قبل العملية، اأو متابعة ذلك التاأثري عند جمموعة خمتارة من املر�ضى. الطريقة: متت هذه الدرا�ضة اال�ضتعادية بني 
يوليو 2009 ومايو 2011م ملفات مبراجعة ملفات جمموعة بها 1,043 مري�ضا يف قاعدة بيانات مر�س �رضطان القولون وامل�ضتقيم يف 
�ضبكة ال�رضطان يف جنوب �رضق ا�ضكتلندا. و�ضملت الدرا�ضة اأي�ضا متابعة حالة 102 مري�ضا من هوؤالء الذين خ�ضعوا لفح�س بالت�ضوير بـ 
وكانت  اجلراحية،  للإزالة  قابل  ال�رضطان  يف  انت�ضار  لديهم  املر�ضى  اأولئك  وكان  التقليدية.  للفحو�س  باالإ�ضافة   18F-FDG-PET/CT
نتائج فح�ضهم بـ CT ملتب�ضة، ولديهم اأي�ضا تركيزات مرتفعة من م�ضت�ضدات �رضطانية م�ضغية عند فح�ضهم بالطرق التقليدية. النتائج: 
قبل العملية، مت عمل فحو�ضات بوا�ضطة 18F-FDG-PET/CT يف 22 من املر�ضى يف هذه الدرا�ضة )وعددهم 102(، ومتت متابعة حاالت 
80 منهم بعد فح�ضهم بوا�ضطة 18F-FDG-PET/CT. ووجد اأنه كان هنالك تاأثري لذلك الفح�س عند 16 مري�ضا )اأي ما ن�ضبته 72.75%(، 
/CT بينما مل يكن للفح�س اأي تاأثري عند �ضتة مر�ضى )اأي بن�ضبة %27.25(. ويف املجموعة التي متت متابعتها بعد العملية كان لفح�س
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Colorectal cancer is one of the most common malignancies in the UK and is a major health problem worldwide.1 Accurate 
disease staging is fundamental to making appropriate 
management decisions. Approximately 20% of cancer 
patients present with distant metastases; if untreated, 
these patients face a five-year survival rate of 7%.1 
Furthermore, local and distant recurrences develop 
in 30–50% of patients during follow-up after primary 
surgery.2 The early detection of recurrence is vital 
because surgery, radiotherapy and chemotherapy 
(either separately or as part of a multidisciplinary 
approach) may improve patient survival and quality of 
life. Although only 20–30% of patients with recurrent 
metastatic disease are suitable candidates for curative 
resection, the five-year survival rate in this group is 
30–40%.3
Metastatic disease in colorectal cancer is most 
commonly detected in the liver or lungs but can 
affect any part of the body. Conventional imaging has 
limitations of sensitivity and specificity depending 
on the disease and the organ affected. For example, 
computed tomography (CT) is usually performed 
for primary staging and surveillance but has a high 
false-positive rate for pulmonary and extrahepatic 
intra-abdominal lesions.4,5 These shortcomings have 
led to the increased use of 18F-fluorodeoxyglucose 
(18F-FDG)-positron emission tomography (PET)/CT 
as an additional imaging modality, both in preoperative 
settings and during follow-up. However, a recent 
review showed this modality to be cost-effective only 
in determining the staging of recurrent colorectal and 
metastatic cancers.6
In the Colorectal Unit of the Western General 
Hospital in Edinburgh, Scotland, 18F-FDG-PET/CT 
scans are performed selectively in patients who appear 
to have potentially curable metastatic disease on 
initial imaging or in those suspected of having occult 
recurrence. The aim of this study was to evaluate the 
clinical impact on patient management of performing 
18F-FDG-PET/CT during preoperative work-up or 
follow-up in a select group of patients.
Methods
This retrospective cohort study took place between 
July 2009 and May 2011. Patient data were retrieved 
from the electronic South East Scotland Cancer 
Network (SCAN) colorectal cancer database 
during the study period. Records from the SCAN 
colorectal cancer database were included in the 
study if the patients had undergone 18F-FDG-PET/
CT in addition to conventional imaging. Indications 
for the use of 18F-FDG-PET/CT were as follows: 
potentially resectable metastases identified by a CT 
scan at primary staging or during post-resection 
surveillance; equivocal CT findings at primary tumour 
staging or during post-resection surveillance, and 
rising carcinogenicembryonic antigen (CEA) levels 
identified by negative conventional imaging during 
follow-up surveillance. 
The following data were recorded from the 
electronic patient record database: primary operative 
procedure; pathological findings; neoadjuvant treat-
ment; indications of the use of 18F-FDG-PET/CT; 
intervals between surgeries and 18F-FDG-PET/CT 
18F-FDG-PET تاأثري مهم يف 51 مري�ضا )اأي ما ن�ضبته %63.75(، وتاأثري قليل عند اأربعة مر�ضى )اأي ما ن�ضبته %5(، وعند 22 مري�ضا 
)اأي ما ن�ضبته %27.5( مل يكن هنالك اأي تاأثري. ووجد اأن لذلك الفح�س تاأثريا �ضار يف ثلثة مر�ضى )%3.75(. اخلال�صة: اأو�ضحت الدرا�ضة 
اأن فحو�ضات 18F-FDG-PET/CT لها اأثر كبري يف معاجلة مر�س �رضطان القولون وامل�ضتقيم عندما جترى يف اأعداد كبرية من املر�ضى 
املحددين.
القولون  �رضطان  جلكوز؛  ديوك�ضي  فلورو  ملادة  امل�ضتخدم  البيزوتروين  االنبعاث  ذو  املقطعي  الت�ضوير  املقطعي؛  الت�ضوير  الكلمات:  مفتاح 
وامل�ضتقيم؛ انت�ضار ال�رضطان؛ حتديد درجة ال�رضطان؛ عودة ال�رضطان؛ م�ضت�ضدات �رضطانية م�ضغية؛ اململكة املتحدة.
Advances in Knowledge
- This study demonstrates that 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) is a 
useful diagnostic tool and can have a valuable impact on the disease management of indicated colorectal cancer patients.
- Only a select group of patients with colorectal cancer, i.e. those with potentially curable disease and resectable metastases, benefit from 
FDG-PET/CT in addition to CT during preoperative work-ups and disease follow-ups. 
- 18F-FDG-PET/CT is beneficial during follow-up treatment for cancer patients, particularly in the identification of occult recurrence 
among those with elevated carcinogenicembryonic antigen levels.
Application to Patient Care
- 18F-FDG-PET/CT is useful in identifying metastatic or recurrent disease at an early stage in patients with colorectal cancer. Early 
identification may improve patient survival.
- Results from 18F-FDG-PET/CT scans can inform disease management in patients with potentially resectable disease or in those with 
equivocal findings from conventional imaging.
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scans (where applicable); results of conventional 
imaging and 18F-FDG-PET/CT scans; clinical actions 
taken after 18F-FDG-PET/CT and/or CT scan results, 
and follow-up information. 
Following data collection, the additional value of 
18F-FDG-PET/CT over conventional imaging was 
assessed with regards to patient management. The 
clinical impact of 18F-FDG-PET/CT was divided 
into the following four categories. 18F-FDG-PET/CT 
imaging was determined to have had a major impact 
if there was evidence of inoperable disease that was 
either indeterminate or occult on prior conventional 
imaging or if there were additional 18F-FDG-PET/
CT findings which had altered disease management. 
Additionally, 18F-FDG-PET/CT was considered to have 
had a minor impact if CT findings were indeterminate 
and 18F-FDG-PET/CT did not identify any disease. 
Imaging was classified as having had no impact when 
18F-FDG-PET/CT showed no additional findings and 
no alterations were made to planned treatments as a 
result. Finally, 18F-FDG-PET/CT scans were deemed to 
have had a potential negative impact in cases of false-
positive findings which had potentially led to further 
investigations or inappropriate disease management.
Ethical approval for this study was granted by the 
Audit Department of Western General Hospital, in 
Edinburgh, Scotland.
Results
A total of 1,043 patients were identified in the SCAN 
colorectal cancer database during the study period. 
Of these, 102 patients had undergone 18F-FDG-PET/
CT as well as conventional imaging either as part of 
primary staging or for disease surveillance. There were 
40 female and 62 male patients. The median age of the 
patients was 63 years (range: 29–88 years). 
A total of 22 patients received 18F-FDG-PET/CT 
for preoperative staging while 80 patients received 
18F-FDG-PET/CT during follow-up. Overall, 18F-FDG-
PET/CT findings were concordant with conventional 
imaging results in only 28 patients (27.4%).
In the preoperative group, potentially resectable 
metastases were detected in 11 patients by 18F-FDG-
PET/CT whereas the other 11 patients had equivocal 
CT findings. Among those with detected resectable 
diseases, CT findings denoting resectable diseases 
were confirmed by 18F-FDG-PET/CT in six cases 
(54.5%). However, three patients whose CT results 
had detected potentially resectable metastases were 
instead deemed inoperable by 18F-FDG-PET/CT. 
Furthermore, two patients were downstaged after 
their 18F-FDG-PET/CT findings were negative. Of the 
11 patients with equivocal CT findings, 18F-FDG-PET/
CT identified six patients with resectable metastases 
and five patients with unresectable metastases. A 
comparison of CT and 18F-FDG-PET/CT findings is 
provided in Table 1. 
In the follow-up group, indications for 18F-FDG-
PET/CT included rising CEA levels identified by 
negative CT results (n = 10), resectable metastases 
or local recurrence on conventional imaging (n = 31) 
and equivocal CT findings (n = 39). The operative 
and pathological details of the patients in the follow-
up group can be seen in Table 2. The mean interval 
between surgery and 18F-FDG-PET/CT scanning was 
587 days (range: 15–2,555 days). Of the 10 patients 
Table 1: Comparison of conventional imaging and 
18F-FDG-PET/CT findings among preoperative colorectal 





Resectable 6 3 2 11
Equivocal 6 5 0 11
CT = computed tomography; 18F-FDG-PET/CT = 18F-fluorodeoxyglucose-
positron emission tomography/computed tomography.
Table 2: Summary of the treatment and pathological 






Anterior resection with TME 33
Abdominoperineal resection of rectum 3
Total colectomy 2
Neoadjuvant treatment 27












TME = total mesorectal resetion; TNM = tumours/nodes/metastases 
staging system.
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with rising CEA levels, two patients had negative 
18F-FDG-PET/CT scan results, five patients were 
found to have resectable disease and three patients 
had unresectable distant metastases. Of the 31 
patients with resectable disease findings on CT scans, 
18F-FDG-PET/CT confirmed these findings in 20 
patients, demonstrated unresectable metastases in 
eight patients and excluded local or distant recurrence 
in three patients. Among the 39 patients with equivocal 
CT findings, 18F-FDG-PET/CT scans demonstrated 
negative results in four patients, resectable local 
recurrence or distant metastases in 22 patients and 
unresectable disease in 13 patients [Figure 1].
Combined 18F-FDG-PET/CT imaging had a 
major clinical impact for 16 patients (72.7%) in the 
preoperative group, including eight patients whose 
treatment was altered from curative to palliative due to 
the presence of inoperable disease, six with resectable 
metastases identified after an indeterminate CT scan 
and two who avoided unnecessary surgery due to 
negative 18F-FDG-PET/CT findings. Furthermore, 
18F-FDG-PET/CT findings had a major impact and 
altered disease management for 51 patients (63.7%) in 
the follow-up group. Of these, 24 patients were offered 
palliative treatment due to findings which indicated 
inoperable recurrent disease that had not been 
diagnosed from CT scans; this included 13 patients 
with indeterminate CT findings, eight whose CT 
findings had indicated resectable metastases and three 
with negative CT results. Resectable recurrent disease 
was found in 24 patients (five and 19 patients with 
negative and indeterminate CT findings, respectively). 
All of the patients who underwent curative resection 
were later confirmed to have recurrent colorectal 
cancer on histological examination. Surgery was 
avoided in three patients whose CT results had 
detected resectable disease but subsequent 18F-FDG-
PET/CT imaging had revealed a negative result. These 
patients remained under close follow-up with no 
clinical or radiological evidence of disease recurrence.
A minor impact on the clinical disease management 
of four patients (5%) in the follow-up group was noted 
due to 18F-FDG-PET/CT imaging. These patients had 
had equivocal CT scan results but were downstaged 
as a result of their 18F-FDG-PET/CT results. Three 
of these patients had lesions detected in their lungs 
and one patient had a liver lesion which was 18F-FDG-
PET/CT-negative and which remained unchanged on 
serial imaging.
Disease management remained unaltered for 
six patients (27.2%) in the preoperative group and 
22 patients (27.5%) in the follow-up group. In these 
cases, 18F-FDG-PET/CT imaging had no impact 
as the combined imaging confirmed the original 
CT findings. In the follow-up group, a total of 20 
patients were found to have recurrent disease while 
two patients with elevated CEA levels had a negative 
result from both CT and 18F-FDG-PET/CT scans. 
Two patients with liver metastases confirmed by CT 
and 18F-FDG-PET/ CT findings refused surgery and 
one patient underwent a hepatic segmentectomy for 
a malignant lesion which had a complete response 
to chemotherapy. 
The clinical impact of 18F-FDG-PET/CT imaging 
was negative in three patients (3.7%) who had 
equivocal CT findings and positive 18F-FDG-PET/
CT results revealing uptake at the anastomotic site. 
All three patients underwent direct visualisation of 
the anastomosis; two via colonoscopies with biopsy 
and one via an examination under anaesthesia 
with biopsy. No histological or clinical evidence of 
disease recurrence was found for any of the patients. 
In addition, one patient underwent excision of an 
umbilical lesion identified on both CT and 18F-FDG-
PET/CT scans. This lesion was later revealed to be 
histologically benign. 
 
Figure 1: Comparison of computed tomography and 18F-fluorodeoxyglucose-positron emission tomography/computed 
tomography findings among colorectal cancer patients during follow-up (N = 80).
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In terms of patient outcomes, 56 patients (54.9%) 
were offered curative surgery and 50 underwent 
metastasectomies as a result of their 18F-FDG-
PET/CT findings. Metastatic lesion resection was 
performed in 46 patients, including the liver only 
(n = 32), the lungs (n = 7), the abdominal wall (n = 3) 
and the peritoneum (n = 3). Additionally, one patient 
underwent a synchronous renal tumour and liver 
resection. Four patients did not undergo surgery; this 
was either due to the progression of the lesion to an 
unresectable form (n = 1), the complete resolution 
of a lung lesion following chemotherapy (n = 1), 
comorbidities (n = 1) or the patient’s choice (n = 1). 
Palliative treatment was offered to 32 patients (31.3%). 
Nine patients (8.8%) were downstaged, three (2.9%) 
were over-investigated (PET/CT showed suspected 
local recurrence but there was no evidence of this 
on endoscopic examination) and two (1.9%) did not 
require further investigations or treatment.
Discussion
The present study investigated the role of 18F-FDG-
PET/CT imaging in the clinical management of 102 
patients with metastatic or recurrent colorectal 
cancer being considered for curative resection. The 
data in the current study showed that 18F-FDG-PET/
CT scans are a useful diagnostic tool in managing 
patients with colorectal cancer since treatment based 
on conventional CT imaging was modified in almost 
two-thirds of the cohort. 
In this study, 18F-FDG-PET/CT findings were 
consistent with conventional imaging findings in 
only 27.4% of the patients, which is much lower than 
other studies reported in the literature.7,8 A possible 
explanation is that 18F-FDG-PET/CT scans were 
carried out selectively among the studied cohort, in 
patients whose management could have been altered 
by the additional imaging. Combined 18F-FDG-PET/
CT imaging proved particularly useful in differentiating 
lesions which were considered indeterminate on CT 
scans, allowing more accurate characterisation in 
almost half of the patients in this cohort.
The liver is the most common site for colorectal 
metastases and the reported sensitivity of 18F-FDG-
PET/CT scans in detecting hepatic metastases varies. 
Selzner et al. found that while 18F-FDG-PET/CT was 
comparable to conventional CT in detecting liver 
lesions, it was superior in detecting extrahepatic 
lesions.9 In their study, 18F-FDG-PET/CT imaging 
was performed on all patients being considered for 
liver metastasis resection and had a major impact on 
21%. A study by Ruers et al. showed that the rate of 
futile laparotomies among their cohort was reduced 
from 45% to 28% through the utilisation of 18F-FDG-
PET/CT scans.10 Weiring et al. also demonstrated the 
utility of 18F-FDG-PET/CT scans, as this modality was 
found to reduce futile laparotomies by 38%.11 There 
have been no large series or comparative studies so 
far between 18F-FDG-PET/CT scans and conventional 
CT scans concerning the detection of pulmonary 
metastases. The accurate determination of pulmonary 
metastases which are indeterminate via CT imaging 
is particularly important if curative resection is being 
considered elsewhere in the body. In the present study, 
six patients with liver metastases were also found to 
have lung metastases on 18F-FDG-PET/CT scans.
Serum CEA levels are commonly monitored 
during follow-up in colorectal cancer patients, in 
addition to physical examinations and conventional 
imaging. While some researchers consider CEA 
levels to be the most effective indicator in detecting 
recurrent disease,12 others have found marginal 
benefits and concluded that the majority of potentially 
curable recurrent tumours are detected by surveillance 
imaging techniques when CEA levels are normal.13,14 
Patients with elevated tumour markers and negative 
results on conventional imaging pose a clinical 
challenge. Several studies have demonstrated the 
value of 18F-FDG-PET/CT imaging in patients with 
rising serum CEA levels and no identifiable lesions on 
conventional imaging.15–17 In the present study, eight 
out of 10 patients with elevated CEA levels were found 
to have metastatic disease even when conventional 
imaging did not show disease recurrence. The other 
two patients with normal 18F-FDG-PET/CT results 
showed no clinical or radiological signs of subsequent 
disease recurrence. Other studies have also reported 
that a negative 18F-FDG-PET/CT scan result is 
accurate in excluding recurrence.18,19 In the case of 
local recurrence at the site of primary colorectal 
cancer, CT findings are often difficult to interpret due 
to benign post-surgical or radiotherapeutical changes. 
Selzner et al. reported a 93% accuracy rate in detecting 
local recurrence with the use of 18F-FDG-PET/
CT imaging.9 However, three out of eight patients 
with equivocal CT results in the current study had 
false-positive 18F-FDG-PET/CT readings, suggesting 
anastomotic recurrence. These cases required direct 
visual examination to exclude disease recurrence.
Although the current study’s results showed that 
the use of 18F-FDG-PET/CT imaging had a primarily 
positive impact on disease management, several 
disadvantages of this modality have been reported. 
Research has indicated that 18F-FDG-PET/CT imaging 
has reduced sensitivity in detecting subcentimetre 
lesions, which means that small metastatic deposits 
can therefore be missed on the scans.20 In addition, 
18F-FDG-PET/CT imaging can reportedly yield 
false-positive readings among patients with benign 
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inflammatory conditions and false-negative readings 
for patients with high blood glucose levels or those 
who have had recent chemotherapy treatments.9,21 
A major limitation of this study was the lack of 
histopathological confirmation of 18F-FDG-PET/CT-
positive lesions in 36 out of 88 patients (41%). This lack 
of histopathological confirmation occurred primarily 
because the distant metastases in question were 
inoperable. The results of this study should therefore 
be interpreted in light of this.
Conclusion
This study demonstrates that, when undertaken in 
selected colorectal cancer patients for clear indications, 
18F-FDG-PET/CT imaging provides valuable infor-
mation and has a considerable impact on disease 
management in a significant proportion of patients. 
This impact was primarily seen via improvements in 
staging accuracy and the avoidance of unnecessary 
surgeries. Additionally, 18F-FDG-PET/CT imaging 
enabled the identification of recurrent disease at an 
early stage at which point curative surgery can be 
offered to the patient. 
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